Enhancing Anti-Tumor Effects of Engineered Extracellular Vesicles via Endocytosis Route Switching and Interferon Response Suppression.

ABSTRACT: Engineered extracellular vesicles (EVs) represent a promising therapeutic strategy with many applications in cancer therapy. EVs derived from engineered tumor-targeting killer cells, such as chimeric antigen receptor (CAR)-T cells. However, the application of CAR-T-EVs is limited by several drawbacks. This study shows that engineered EVs with potent cancer-targeting and killing abilities can be generated from easily manipulable non-killer cells, providing a solution to overcome the limitations of CAR-T-EVs. It is found that EVs derived from non-killer cells such as CD19-targeting 293 cells possess target cell killing capacities comparable to those derived from CD19-CAR-T cells. A technique is developed to ensure the presence of sufficient targeting modules on the EV surface using a chimeri

SUBMITTER: Huang Z 

PROVIDER: S-EPMC12697815 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature